[State of unmet medical needs in France in 2006: necessity of reinforcing research effort].
Leem (French Pharmaceutical Companies) realized an inventory of unmet medical needs in 2006 in France for 12 pathologies. All of them are considered as national public health priorities by the law of August 9th, 2004. Allied to the epidemiological projections, analyses concerned various stages and/or pathology forms, impact of guidelines in clinical practice, therapeutic strategies, marketed therapeutics and pharmacological products in an advanced phase of clinical development. With more than 100 products listed in clinical phase III or pre-registration/marketed for those pathologies, French Pharmaceutical Companies contribute, quasi exclusively, to the development of innovative pharmaceutical products to answer unmet medical needs. This study illustrates the necessity of French Government to support therapeutic innovation led by Pharmaceutical Companies in France.
Jouan-Flahault
Chrystel
C
Les Entreprises du médicament (Leem), Paris, France. cjouan-flahault@leem.org
Billon
Nathalie
N
Castaigne
Alain
A
Henry
Yves-Dominique
YD
Omnes
Carole
C
Puech
Alain
A
Rosilio
Myriam
M
Lassale
Catherine
C
D004345:Drug Industry; D004358:Drug Therapy / Q000191:economics / Q000592:standards / Q000639:trends*; D005602:France / Q000453:epidemiology; D006801:Humans; D020380:Needs Assessment / Q000639:trends*; D009765:Obesity / Q000453:epidemiology / Q000534:rehabilitation; D011634:Public Health / Q000639:trends; D012106:Research / Q000639:trends*